Characterizing patients with rare mucormycosis infections using real-world data

Yayue Zhang1*, Anita H. Sung2, Emily Rubinstein2, Michael Benigno2, Richard Chambers2, Nataly Patino2 and Jalal A. Aram2

Abstract

Background: Invasive mucormycosis (IM) is a rare and often life-threatening fungal infection, for which clinical and epidemiological understanding is lacking. Electronic health record (EHR) data can be utilized to elucidate large populations of patients with IM to address this unmet need. This study aimed to descriptively assess data on patients with IM using the Optum® EHR dataset.

Methods: US patient data from the Optum® deidentified EHR dataset (2007–2019) were analyzed to identify patients with IM. Patients with hematologic malignancies (HM), at high risk of IM, were selected and sorted by IM diagnosis (ICD9 117.7; ICD10 B46). Demographics, comorbidities/other diagnoses, and treatments were analyzed in patients with IM.

Results: In total, 1133 patients with HM and IM were identified. Most were between 40 and 64 years of age, Caucasian, and from the Midwest. Essential primary hypertension (50.31%) was the most common comorbidity. Of the 1133 patients, only 33.72% were prescribed an antifungal treatment. The most common antifungal treatments were fluconazole (24.27%) and posaconazole (16.33%), which may have been prophylactic, and any AmB (15.62%).

Conclusions: A large population of patients with IM were identified, highlighting the potential of analyzing EHR data to investigate epidemiology, diagnosis, and the treatment of apparently rare diseases.

Keywords: Invasive mucormycosis, Zygomycosis, Electronic health records, Hematologic malignancies, Epidemiology, Real-world data

Background

Invasive mucormycosis (IM) is a rare and life-threatening invasive fungal infection caused by fungal species of the order Mucorales [1–3]. Mortality of patients with IM has been observed to range from 20–78%, although the small number of patients in these studies limits the reliability of these results [4, 5]. The term ‘zygomycosis’ is often used synonymously with mucormycosis, but also includes infections with species of the order Entomophthorales [3]. IM diagnoses are categorized, according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group, as ‘proven’, ‘probable’, or ‘possible’ [6]. ‘Proven’ IM is diagnosed with certainty by the established presence of fungi; ‘probable’ IM is suggested by the presence of host factor criteria, clinical features, and mycological evidence; ‘possible’ IM is suggested by the presence of only host factor criteria [7]. Diagnostic techniques include radiological procedures (for example, chest and cranial CT scans and cranial MRIs), microbiological procedures (including quantitative PCR, high-resolution melting, and multiplex targeting) and histological procedures (including biopsies, direct microscopy using fluorescent brightener, and...
histopathology with stains such as periodic acid–Schiff and Grocott-Gomori methenamine silver stain) [8, 9].

Diagnosis of IM through these procedures is difficult, because fungal elements may not be detected in biopsies due to unviable fungal elements in homogenized tissues and, if present, may be fragmented in patient samples [8]. Additionally, clinical, radiographic, and cytological procedures have limited sensitivity, and the time taken to produce results can delay diagnosis [10]. As a result, diagnosis by autopsy or in the 24 h before death has been reported in around 10–46% of cases when studied [8, 11]. Diagnosis at a late stage of disease progression can delay treatment, leading to an increased risk of treatment failure and increased mortality [8, 12]. Although molecular diagnostic procedures are available, radiographic and biopsy sampling diagnoses are still often used [10].

The majority of patients with IM are immunocompromised, and previous studies have shown that 44–62% of patients have hematologic malignancies (HMs) [11, 13]. Previous epidemiological studies in patients with IM identified acute myeloid leukemia (48–51% of patients) and acute lymphoblastic leukemia (22–27% of patients) as the most commonly observed malignancies [8, 11]. Treatment recommendations for IM include liposomal amphotericin B (AmB) or, in the case of pre-existing renal compromise, intravenous isavuconazonium sulfate or posaconazole [9], as well as prophylactic treatment with azoles in neutropenic patients and surgical resection in combination with the last known effective treatment in immunosuppressed patients with a prior IM diagnosis [14]. Surgery in combination with antifungal treatment, most commonly 5–10 mg/kg/day liposomal AmB, is strongly recommended as a first-line therapy in adult patients with IM [9, 14].

Due to the rarity of IM, clinical, epidemiological, and outcomes data are lacking and are largely limited to case studies [1, 2, 15]. Large administrative datasets, for example claims databases and electronic health records (EHRs), are increasingly being used to facilitate analyses across many therapy areas [16]. Analysis of large datasets can be applied to many aspects of healthcare research, including epidemiology, pharmacovigilance, clinical trial recruitment, health economics and outcomes research, drug discovery, and diagnostics [16–18].

One example of a large dataset is the Optum® deidentified EHR dataset (2007–2019), which contains data from approximately 97 million patients from the USA. These data provide the opportunity to assess the population size and characteristics of patients with IM in a real-world setting, within the general population. This study aimed to descriptively assess data on patients with IM using the Optum® EHR dataset. It is hoped that characterizing a large pool of patient data will facilitate comparisons between real-world data and existing case studies, which will improve the diagnosis and treatment of this rare and life-threatening infection in the coming years.

**Methods**

**Study data**

This retrospective, observational study was conducted using patient data from the Optum® deidentified EHR dataset (2007–2019). The Optum® data acquisition model aggregates deidentified EHR data from providers across the continuum of care.

Optum®’s longitudinal EHR repository is derived from dozens of healthcare provider organizations in the United States that include more than 700 hospitals and 7000 clinics, and treat more than 103 million patients receiving care. The data are certified as deidentified by an independent statistical expert following Health Insurance Portability and Accountability Act statistical deidentification rules, and managed according to Optum® customer data use agreements [19, 20]. Clinical, claims, and other medical administrative data are obtained from both inpatient and ambulatory EHRs, practice management systems, and numerous other internal systems. Information is processed, normalized, and standardized across the continuum of care from both acute inpatient stays and outpatient visits. Optum® data elements include: demographics, medications prescribed and administered, immunizations, allergies, laboratory results (including microbiology), vital signs and other observable measurements, clinical and inpatient stay administrative data, and coded diagnoses and procedures.

**Patient selection**

Patients (male or female of any age) with any diagnosis of HM, who would be in the high IM risk category, were included in the analyses to reduce the possibility of false IM coding. International classification of diseases, ICD9 (pre-October 2015) and ICD10 (from October 2015), codes were then used to group patients into the following sub-evaluation cohorts: acute myeloid leukemia (AML), other lymphomas, other leukemias and other HM, as well as patients with neutropenia and stem cell transplants. ICD codes (ICD9 117.7; ICD10 B46.x) were then used to identify patients with IM from the HM cohort. Note that the method of diagnosis could not be retrospectively confirmed from deidentified patient data. The index date was the diagnosis of HM, and the observation period was at least 6 months of follow-up, including the assessment of IM (Fig. 1).

Among the overall HM cohort, patients with invasive aspergillosis (IA) infection (ICD9 117.3, 117.9, 484.6, 518.6; ICD10 B44.0, B44.1, B44.7) or coinfection with IM and IA within 360 days post-index were also explored.
Treatment outcomes and mortality rates were not available in the dataset.

Statistical analyses

Descriptive statistics were used to analyze demographics, comorbidities, and other diagnoses (including mean Charlson Comorbidity Index [CCI] score [21, 22]) and treatments in the patient sample. No statistical hypotheses were tested.

Results

Patient demographics and clinical characteristics

Approximately 100 million patients were included in the Optum® EHR dataset at the time of the analysis. Of these, 962,428 patients had an HM, and 1133 (0.001% of the overall patient population, 0.12% of HM) had an IM diagnosis (Table 1).

In the 1133 patients with HM and IM, diagnosis of IM occurred after the diagnosis of HM in 95.94% of patients. HM and IM were diagnosed on the same day in the remaining 4.06% of patients. Of the 962,428 patients with HM, a total of 10,638 (1.11%) were diagnosed with IA. There were 161 patients in the HM cohort coinfected with IA and IM (14.21% of all patients with HM and IM).

Among the patients with HM and IM, the ICD9/ICD10 HM diagnoses were neutropenia (332 patients, 29.30%), leukemia (208 patients, 18.36%), lymphoma (165 patients, 14.56%), AML (145 patients, 12.80%), stem cell transplant (106 patients, 9.36%), and other HM (102 patients, 9.00%). Among patients with HM and IM with index events during the years 2007 through 2019, about one-fifth of IM cases identified occurred during each of the years 2015, 2016, and 2017, whereas fewer cases were identified in earlier years.

In the overall HM cohort, most patients were 40–64 years of age (374,517 patients, 38.91%) or > 65 years of age (355,453 patients, 36.93%), and the majority were Caucasian (757,088 patients, 78.66%) and from the Midwest region (505,791 patients, 52.55%). Just over half (542,919 patients, 56.41%) were female. Similarly, in patients with HM and IM, most were 40–64 years of age (601 patients, 53.05%) or > 65 years of age (340 patients, 30.01%), and the majority were Caucasian (968 patients, 85.44%) and from the Midwest region (951 patients, 83.94%). As with the overall HM cohort, just over half of patients with HM and IM (644 patients, 56.84%) were female (Table 2).

Of the 1133 patients with HM and IM, clinical forms of mucormycosis (specified and unspecified) were identified by ICD10 code in 292 patients. Of these, the clinical form was specified in 129 patients, with the most common being pulmonary mucormycosis (45 patients, 3.97%). Clinical forms of mucormycosis were not identified in the remaining 841 patients, as these patients were identified only by the ICD9 code 117.7.

Comorbidities and other diagnoses

The mean CCI score in patients with HM and IM was 3.52 (SD 2.11) post-index. Most patients (1100 patients; 97.09%) had a Charlson Comorbidity Condition. Four patients (0.35%) had HIV/AIDS. The most common comorbidity in the overall HM cohort, based on ICD

| Group selection steps | Patients | % of total patients | % of patients in step 2 (1) |
|----------------------|----------|---------------------|-----------------------------|
| 1. All the patients enrolled during Jan 2007–Jun 2019 in Optum® | 101,340,454 | 100.00 | – |
| 2. (1) and with HM and 6 months follow-up | 962,428 | 0.95 | 100.00 |
| 3. (2) and with IA between index and enrollment end date | 10,638 | 0.01 | 1.11 |
| 4. (2) and with IM between index and enrollment end date | 1133 | 0.00 | 0.12 |
| 5. (2) and coinfected with IA and IM within 360 days post-index | 161 | 0.00 | 0.02 |

(1) Refers to the overall total number of 101,340,454 patients
(2) Refers to the 962,428 patients with HM and 6 months follow-up

EHR electronic health record, HM hematologic malignancy, IA invasive aspergillosis, IM invasive mucormycosis
codes, was hypertension [unspecified essential (243,860 patients, 25.34%) and essential primary (233,997 patients, 24.31%); Table 3]. In addition to hypertension, comorbidities observed in >15% of patients included other/unspecified hyperlipidemia [166,752 patients, 17.33% (ICD9); 144,349 patients, 15.00% (ICD10)], encounter for immunization [162,653 patients, 16.90% (ICD10)], unspecified anemia [157,597 patients, 16.37% (ICD9)], and other long-term drug therapy [147,499 patients, 15.33% (ICD10); Table 3]. In patients with HM and IM, the most common (n > 200) comorbidities and other diagnoses, based on ICD9 and ICD10 codes, included essential primary hypertension (570 patients, 50.31%), unspecified essential hypertension (463 patients, 40.86%), and long-term (current) use of other medications [302 patients, 26.65% (ICD9); 416 patients, 36.72% (ICD10); Table 3]. Diabetes mellitus without complications was observed in 17.92% (ICD9) and 18.80% (ICD10) of patients with HM and IM (Table 3).

Treatments

In the overall HM cohort, 119,414 patients were prescribed an antifungal treatment within 360 days post-index. The most commonly prescribed antifungal treatment was fluconazole (109,372 patients, 91.59% of HM patients with antifungal prescriptions).

Of the 119,414 patients with HM who had also been prescribed an antifungal treatment, 382 (0.32% of HM cohort; 33.72% of HM and IM cohort) had IM, while 751 patients (66.28%) with IM received no antifungal treatment (Table 4).

Of the 382 patients with HM and IM who had been prescribed an antifungal agent, the most common were fluconazole (275 patients, 71.99%), posaconazole (185 patients, 48.43%), and AmB (177 patients, 46.34%), indicating that most patients received multiple antifungal agents. In the 122 patients coinfected with IM and IA, the most commonly prescribed antifungal agents were AmB (93 patients, 76.23%), posaconazole (86 patients, 70.49%), fluconazole (72 patients, 59.02%), and voriconazole (70 patients, 57.38%), also demonstrating that these patients receive multiple antifungal agents.

Discussion

In this retrospective, observational study using US patient data from the Optum® EHR dataset, we identified 1133 patients with a diagnosis of HM and IM. Of these patients, most were Caucasian, >40 years of age, and located in the Midwest region of the USA. It should be noted, however, that the majority of patients in the overall HM cohort in this study were localized in the Midwest, so these characteristics are not necessarily associated with IM. Common comorbidities and other diagnoses included essential hypertension, malignant neoplasm of connective and other soft tissue, long-term use of other medications, encounter for immunization, and hyperlipidemia. The most commonly prescribed antifungal agents in this group were fluconazole, posaconazole, and any AmB.

The 1133 patients that we identified with HM and IM were comparatively large versus those of other studies, in which the number of patients with IM ranged from

| Table 2 Demographic and clinical characteristics of patients with HM and patients with HM and IM |
|---------------------------------------------------------------|
| **Overall HM cohort** | **HM and IM cohort** |
| **n** | **%** | **n** | **%** |
| **Age group** | | | |
| 0–12 | 68,892 | 7.16 | 40 | 3.53 |
| 13–17 | 23,548 | 2.45 | 13 | 1.15 |
| 18–39 | 139,684 | 14.51 | 601 | 53.05 |
| 40–64 | 374,517 | 39.81 | 340 | 30.01 |
| 65+ | 355,453 | 36.93 | | |
| **Sex** | | | |
| Female | 542,919 | 56.41 | 644 | 56.84 |
| Male | 418,637 | 43.50 | 489 | 43.16 |
| **Race** | | | |
| African American | 100,958 | 10.49 | 64 | 5.67 |
| Asian | 15,613 | 1.62 | 14 | 1.24 |
| Caucasian | 757,088 | 78.66 | 968 | 85.44 |
| Other/unknown | 88,769 | 9.22 | 67 | 5.91 |
| **Ethnicity** | | | |
| Hispanic | 40,235 | 4.18 | 52 | 4.59 |
| Non-Hispanic | 826,907 | 85.92 | 1035 | 91.35 |
| Unknown | 95,286 | 9.90 | 46 | 4.06 |
| **US region** | | | |
| Midwest | 505,791 | 52.55 | 951 | 83.94 |
| Northeast | 129,764 | 13.48 | 38 | 3.35 |
| South | 203,603 | 21.16 | 90 | 7.94 |
| West | 92,147 | 9.57 | 40 | 3.53 |
| Other/unknown | 31,123 | 3.23 | 14 | 1.24 |
| **Clinical forms of IM** | | | |
| Pulmonary mucormycosis | – | – | 45 | 3.97 |
| Rhinocerebral mucormycosis | – | – | 35 | 3.09 |
| Gastrointestinal mucormycosis | – | – | 0 | 0.00 |
| Cutaneous mucormycosis | – | – | 29 | 2.56 |
| Disseminated mucormycosis | – | – | 12 | 1.06 |
| Mucormycosis, unspecified | – | – | 109 | 9.62 |
| Other zoymycoses | – | – | 8 | 0.71 |
| Zygomycosis, unspecified | – | – | 54 | 4.77 |

HM hematologic malignancy, IM invasive mucormycosis, N the total number of patients, n number of patients in the category.
41–851 patients [1, 8, 11, 13, 15, 23], suggesting that IM infection could be more common than existing studies show. In contrast to our study, the majority of patients in these studies were European, and the data were pooled either from prior clinical records, mycology surveys, or voluntary case registries. In one global study of 851 individual patient case reports, similar proportions of European (34%), Asian (31%), and North and South American patients (28%) were observed [23], although under-reporting may be occurring in some countries [24]. Notably, the proportion of females with IM (56.84%) was higher in the current study compared with that observed in other studies, in which the proportion of females ranged from 30–40% [11, 13, 15]; however, this could be explained by the fact that there was a higher proportion of female patients than male patients in the overall HM cohort in this study.

Several studies have identified a large number (ranging from 44.00–63.40%) of patients with IM and underlying HM [1, 11, 15]. Because IM is rare and difficult to diagnose, this study focused on patients with HM to enrich the population with true IM infections and reduce the possibility of false IM coding. Other than diabetes mellitus, which was observed in a slightly higher proportion (17.92%) compared with that observed in other studies (4.80–17.10%), the most common comorbidities and other diagnoses in this study were not observed elsewhere [1, 11, 15]. Diabetes mellitus is a known risk factor associated with IM, so it was not surprising that it was observed in a large proportion of patients with IM in our study [25]. The most common non-HM comorbidity in patients with HM and IM was essential primary hypertension (50.31% of patients), which seemed to be a unique finding compared with

| Comorbidity/other diagnosis                                      | ICD code   | n         | (%)     |
|-----------------------------------------------------------------|------------|-----------|---------|
| Patients with HM                                                |            |           |         |
| Unspecified essential hypertension                               | ICD9 401.9 | 243,860   | 25.34   |
| Essential (primary) hypertension                                | ICD10 I10 | 233,997   | 24.31   |
| Other and unspecified hyperlipidemia                            | ICD9 272.4 | 166,752   | 17.33   |
| Encounter for immunization                                      | ICD10 Z23 | 162,653   | 16.90   |
| Anemia, unspecified                                             | ICD9 285.9 | 157,597   | 16.37   |
| Other long-term (current) drug therapy                          | ICD10 Z79.899 | 147,499   | 15.33   |
| Hyperlipidemia, unspecified                                     | ICD10 E78.5 | 144,349   | 15.00   |
| Long-term (current) use of other medications                    | ICD9V58.69 | 135,159   | 14.04   |
| Neutropenia, unspecified                                        | ICD9 288.00 | 134,233   | 13.95   |
| Encounter for general adult medical examination without abnormal findings | ICD10 Z00.00 | 123,282   | 12.81   |
| Anemia, unspecified                                             | ICD10 D64.9 | 120,963   | 12.57   |
| Patients with HM and IM                                          |            |           |         |
| Essential primary hypertension                                  | ICD10 I10 | 570       | 50.31   |
| Unspecified essential hypertension                               | ICD9 401.9 | 463       | 40.86   |
| Malignant neoplasm of connective and other soft tissue          | ICD9 171   | 313       | 27.63   |
| Long-term (current) use of other medications                    | ICD9V58.69 | 302       | 26.65   |
| Other long-term (current) drug therapy                          | ICD10 Z79.899 | 416       | 36.72   |
| Encounter for immunization                                      | ICD10 Z23 | 335       | 29.57   |
| Other and unspecified hyperlipidemia                            | ICD9 272.4 | 300       | 26.48   |
| Hyperlipidemia, unspecified                                     | ICD10 E78.5 | 329       | 29.04   |
| Long-term (current) use of other medications                    | ICD9 288.00 | 302       | 26.65   |
| Other and unspecified hyperlipidemia                            | ICD10 Z79.899 | 416       | 36.72   |
| Encounter for general adult medical examination without abnormal findings | ICD10 Z00.00 | 123,282   | 12.81   |
| Other and unspecified hypertension                              | ICD9 285.9 | 157,597   | 16.37   |
| Malignant neoplasm of connective and other soft tissue          | ICD9 171   | 313       | 27.63   |
| Anemia, unspecified                                             | ICD9 401.9 | 243,860   | 25.34   |
| Encounte...
Table 4 The antifungal treatment prescribed to patients with hematologic malignancy and invasive mucormycosis

|                                | Overall HM cohort N=962,428 | HM and IM cohort N=1133 |
|--------------------------------|-----------------------------|-------------------------|
|                                | n   | %  | n   | %  |
| Any antifungal treatment       | 119,414 | 12.41 | 382 | 33.72 |
| Fluconazole                    | 109,372 | 11.36 | 275 | 24.27 |
| Voriconazole                   | 9657 | 1.00 | 137 | 12.09 |
| Micafungin                     | 9443 | 0.98 | 72 | 6.35 |
| Posaconazole                   | 5080 | 0.53 | 185 | 16.33 |
| Any amphotericin B             | 3521 | 0.37 | 177 | 15.62 |
| Itraconazole                   | 2685 | 0.28 | 24 | 2.12 |
| Caspofungin                    | 2635 | 0.27 | 56 | 4.94 |
| Anidulafungin                  | 1972 | 0.20 | 16 | 1.41 |
| Isavuconazole                  | 825 | 0.09 | 59 | 5.21 |

HM hematologic malignancy, IM invasive mucormycosis, N the total number of patients, n number of patients in the category

pooled data studies, although this could be because there was a large proportion of patients with hypertension in the overall HM cohort, and a large proportion of patients of ≥ 65 years of age. Interestingly, however, a history of hypertension has been observed in some individual case studies of patients with IM, suggesting a potential association between hypertension and IM that has not been reported in a larger patient population [26–28]. Additional research into these findings could help to further our understanding of the potential predictors of IM in patients with HM.

Of the patients with HM who were prescribed any antifungal, only 0.32% had IM, which could reflect the challenges associated with the efficient diagnosis and treatment of IM. While AmB is strongly recommended as a first-line therapy for IM [14], only a relatively small percentage of patients with HM and IM in our study (15.62%) received AmB treatment compared with other studies, in which the percentage of AmB-treated patients (monotherapy or in combination with other treatments) ranged from 59.46–72.61%. However, only around one-third of patients with HM and IM received any antifungal treatment and, of these, 46.34% received AmB; this again highlights the challenges associated with the diagnosis and treatment of IM but suggests that AmB is prescribed commonly in the patients who are diagnosed and treated. Aside from AmB, the most commonly prescribed antifungal treatments in our study (patients with HM and IM; patients with HM and IM who received any antifungal, respectively) were the azoles, fluconazole (24.27%; 71.99%), and posaconazole (16.33%; 48.43%), suggesting that many patients received more than one antifungal agent. The high number of fluconazole prescriptions is surprising, given that fluconazole is not mold active [29, 30]. This could be influenced by the fact that fluconazole and posaconazole are often used as long-term prophylactic treatments in patients with neutropenia [9, 14]. Prophylactic treatment strategies may lead to overuse of antifungals, causing unnecessary exposure and the potential development of resistance, as well as an increased cost burden [31]. Antifungal stewardship (AFS) programs can be utilized to monitor and intervene in antifungal treatment strategies, although cultural and professional influences may present a barrier to the usefulness of AFS [31, 32]. The data presented here may help to illustrate large-scale prescribing behaviors, although more research is necessary to further our understanding of antifungal prescribing behaviors and reduce inappropriate antifungal use.

The frequency of azole use may have been associated with the prevention or treatment of IA. Posaconazole, for example, is recommended for salvage treatment and prophylaxis against IA [30]. However, some evidence suggests that prophylactic azoles do not prevent IM [33] and have been associated with breakthrough IM infections in some patients [11, 15]. Although coinfection with IA and IM is considered rare [34], it was observed in 14.21% of the patients with HM and IM in the current study, suggesting that it may be more common than previous patient data have indicated. Further study and increased clinical awareness of IA and IM coinfection may lead to improved diagnosis and treatment in the coming years.

This study was descriptive only, with observational data, and yielded a high-level epidemiologic view. No statistical inference testing was performed, and no outcomes data, including survival, were available; therefore, further study is required to draw meaningful conclusions from the data. There are inherent limitations with large patient datasets and how the data are collected and recorded. For example, the HM cohort mainly includes patients localized in the Midwest, which may not represent the wider population of IM patients. There were also more data available in recent years compared with earlier years, suggesting an increase over time in the number of patients with data recorded in EHR datasets. Additionally, the data were not collected for research purposes, so it may be more difficult to analyze compared with clinical data. For example, Mucorales species and the method of diagnosis could not be extracted from the data. Finally, diseases could have been miscoded, and it was not possible to retrospectively confirm diagnoses from the deidentified patient data. Despite the inherent limitations of analyzing large patient datasets, the potential benefit
of this approach has been shown in this study. However, these limitations should be taken into account in future studies.

Conclusion
In conclusion, this study represents a promising new approach for analyzing large cohorts of patients with apparently rare diseases, which are challenging to identify prospectively. With further study, the potential applications of large dataset analysis for patients with IM include identifying risk factors, improving diagnosis, and assessing current treatment practices and outcomes. Implementation of research standards, harmonized guidance and more sophisticated methods will facilitate the continuation of informative research in future real-world studies.

Abbreviations
AmB: Amphotericin B; AFS: Antifungal stewardship; AML: Acute myeloid leukemia; CCI: Charlson Comorbidity Index; EHR: Electronic health record; HM: Hematologic malignancy; IA: Invasive aspergillosis; ICD: International classification of diseases; IM: Invasive mucormycosis; N: The total number of patients; n: Number of patients in the category.

Authors’ contributions
All authors (YZ, AHS, ER, MB, RC, NP and JAA) contributed to the study design, reviewed the manuscript for intellectual content, and approved the final version for submission. AHS, ER, MB, RC and JAA also contributed to the data analysis and interpretation. All authors read and approved the final manuscript.

Funding
This study was funded by Pfizer Inc, New York, NY, USA. Employees of the sponsor were involved in study conception, design, and conduct, and in data collection and analysis. Medical writing support, under the direction of the authors, was provided by Molly MacFadyen, MSc, CMC Connect, McCann Health Medical Communications, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–4).

Availability of data and materials
The data that support the findings of this study are available from Optum® but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. The license allows Pfizer to access currently available data from the Optum® deidentified EHR dataset, which is subject to change over time in line with changes to the network. Data are however available from the authors upon reasonable request and with permission of Optum®. Please contact the corresponding author of this manuscript (Yayue Zhang, zhangyayue@gmx.com) or Optum® directly (yunwei.sun@optum.com) if you would like to request data, or require any further information.

Declarations
Ethics approval and consent to participate
No ethical approval was required for this study, as it used deidentified patient data from the Optum® EHR dataset. Data was accessed from Optum® and used under license for the current study. The license allows Pfizer to access currently available data from the Optum® deidentified EHR dataset.

Consent for publication
Not applicable.

Competing interests
AHS, MB, RC, NP and JAA are employees of, and hold shares in, Pfizer Inc. ER is a former employee of Pfizer Inc. ZY has no conflicts of interest to declare.

Author details
1Hematology and Oncology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Hai Yun Cang on the 5th Zip, Dongcheng District, Beijing, China. 2Pfizer Inc, Hospital BU, 23 East 42nd Street, New York, NY 10017, USA.

Received: 10 November 2020   Accepted: 31 January 2022
Published online: 14 February 2022

References
1. Pana ZD, Seidel D, Skiaeta A, Groll AH, Petrikko G, Cornely OA, Rolides E. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016;16(1):667.
2. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schauefe RL, Sein M, Sein T, Chou CC, Chu JH, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.
3. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoromycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54(Suppl. 1):S8–15.
4. Zilberberg MD, Shorr AF, Huang H, Chaudhari P, Palv VF, Menzin J. Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data. BMC Infect Dis. 2014;14:310.
5. Hammond SP, Baden LR. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother. 2011;55(11):5018–21.
6. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra TF, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813–21.
7. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7–14.
8. Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Picardi M, Corvatta L, D’Antonio D, Girmenia C, Martinot P, et al. Mucormycosis in hematologic patients. Haematologica. 2004;89(2):207–14.
9. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoening M, Jensen HE, Lagrou K, Lewis RE, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405–21.
10. Walsh TJ, Gamaletidou SM, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54(Suppl. 1):555–60.
11. Skiaeta A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaudard P, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European confederation of medical mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–67.
12. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(6):503–9.
13. Pagano L, Valenti CG, Posteraro B, Girmenia C, Oss C, Pan A, Candoni A, Nosari A, Riva M, Cattaneo C, et al. Zygomycosis in Italy: a survey of
